

Corresponding Author Mail id : vichen@med.umich.edu

Editorial: clinical outcomes in lean NAFLD – the key may be in the details. Authors' reply

Authors: Karn Wijarnpreecha¹, Anna S. Lok², and Vincent L. Chen²

1. Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine - Phoenix, Phoenix, AZ, USA
2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA

We read with great interest the editorial by Tan et al on our recent study on clinical outcomes in patients with lean non-alcoholic fatty liver disease (NAFLD), where we found that lean patients with NAFLD experienced higher mortality than patients with overweight or obesity, despite lower prevalence of baseline metabolic disease and lower incidence of cirrhosis and diabetes ¹.

We would like to clarify how our cohort was generated and the rationale for this approach ². We identified patients with hepatic steatosis based on simple natural language processing algorithms applied to imaging, biopsy, and vibration-controlled transient elastography reports. We used this approach with the aim of identifying consecutive patients with objective evidence of hepatic steatosis and to avoid referral biases inherent in cohorts based in subspecialty clinics who typically have more advanced disease ^{3,4}. This approach inevitably includes a high proportion of patients with incidental diagnoses of NAFLD: we previously found that the most common indication for abdominal imaging in our center was abdominal pain or other abdominal symptoms (44%) which are unlikely to be caused by NAFLD ⁵.

Tan et al correctly point out several limitations of our study. First, our study was based out of a single medical center, though we included the entire spectrum of care from primary care through subspecialty care. Fewer than 10% of the patients in our cohort were followed in hepatology clinic ⁶. Second, our cohort included patients with incidental and early-stage NAFLD not severe enough to warrant biopsy or even elastography. As detailed above, we consider our approach to be more reflective of “real-world” NAFLD in that patients not seen in subspecialty clinic could nonetheless be included. We conducted a sensitivity analysis stratified based on Fibrosis-4 scores to account for baseline disease severity. There was no overall change in our findings with this analysis.

Third, Tan et al point out that some lean patients with NAFLD may have died of unrelated diseases due to a higher burden of comorbidities. We agree with this point, which is especially relevant since patients with

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/apt.17453

comorbidities may have been more likely to undergo imaging resulting in a NAFLD diagnosis⁵. We addressed this question via a sensitivity analysis adjusting for Charlson comorbidity index, a commonly-used score to quantify disease burden, and lean body mass index remained associated with higher mortality. However, we acknowledge the risk of residual confounding, especially with diseases that are not included in the Charlson comorbidity index.

Lean NAFLD is a growing health concern worldwide which affects over 5% of the general population and up to 20% of patients with NAFLD⁷. Our study along with others found that lean patients with NAFLD may have higher mortality than their overweight/obese counterparts⁸, but we acknowledge the limitations in our study outlined in the editorial and stress that our findings should be interpreted with caution in light of them.

Further research into the impact of lean NAFLD and mechanisms of disease is crucial to understanding and treating lean NAFLD.

Author contributions:

Karn Wijarnpreecha: Writing – review and editing

Anna Lok: Writing – review and editing

Vincent Chen: Writing – original draft

Disclosures:

The authors' declarations of personal conflicts of interest are unchanged from those in the original article².

References:

1. Tan EX, Muthiah MD, Ng CH, Huang DQ. Editorial: clinical outcomes in lean NAFLD – the key may be in the details. *Aliment Pharmacol Ther.* 2023; in press.
2. Wijarnpreecha K, Li F, Lundin SK, et al. Higher mortality among lean patients with nonalcoholic fatty liver disease despite fewer metabolic comorbidities. *Aliment Pharmacol Ther.* 2023; in press.
3. Kang KA, Jun DW, Kim MS, Kwon HJ, Nguyen MH. Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population. *Aliment Pharmacol Ther.* 2020;51(3):388-396.
4. Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. *Lancet Gastroenterol Hepatol.* 2017;2(4):288-297.
5. DiBattista JV, Burkholder DA, Lok AS, Chen VL. Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort. *Digestive Diseases and Sciences.* 2022.
6. DiBattista JV, Lok AS, Chen VL. Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis. *Hepatol Commun.* 2023;7(3):e0044.

7. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *The Lancet Gastroenterology & Hepatology*. 2020;5(8):739-752.
8. Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2022.